This is a repository copy of *Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/117275/

Version: Accepted Version

**Article:**
George, MD, Østergaard, M, Conaghan, PG orcid.org/0000-0002-3478-5665 et al. (3 more authors) (2017) Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76 (10). pp. 1743-1746. ISSN 0003-4967

https://doi.org/10.1136/annrheumdis-2017-211569

© 2017, Article author(s) (or their employer(s) unless otherwise stated in the text of the article). This is an author produced version of a paper published in Annals of the Rheumatic Diseases. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Obesity and Rates of Clinical Remission and Low Magnetic Resonance Imaging Inflammation in Rheumatoid Arthritis

Michael George, MD, MSCE
Mikkel Østergaard, MD, PhD, DMSc
Philip G. Conaghan, MD, PhD
Paul Emery, MD
Daniel G. Baker, MD
Joshua F. Baker, MD, MSCE

1. Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
2. University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
3. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
4. Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
5. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen Denmark.
6. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds UK
7. Janssen Research & Development, LLC., Horsham PA, USA

Corresponding Author:
Michael George, MD MSCE
Hospital of the University of Pennsylvania
Division of Rheumatology
5 White Building, 3400 Spruce St
Philadelphia, PA 19104
Phone: 215-662-2789
Fax: 215-662-4500
Email: michael.george@uphs.upenn.edu

Word count: 1497
ABSTRACT

Objectives: Obesity has been proposed as a risk factor for refractory rheumatoid arthritis (RA). We evaluated the impact of obesity on achieving clinical and imaging definitions of low disease activity.

Methods: This study evaluated 470 patients with RA from GO-BEFORE and GO-FORWARD randomized clinical trials. Included patients had blinded clinical disease activity measures and magnetic resonance imaging (MRI) at baseline, 24, and 52 weeks. Synovitis, osteitis, and total inflammation scores were determined using the RA MRI scoring system. Multivariable logistic regression analyses compared odds of achieving Disease Activity Score [DAS28(CRP)] remission, low component measures, or low MRI inflammation measures at 24 weeks in obese versus non-obese patients.

Results: At 24 weeks, obese patients were significantly less likely to achieve DAS28(CRP) remission [OR (95% CI): 0.47 (0.24-0.92), p=0.03]. In contrast, obese patients had similar odds of achieving low synovitis [OR 0.94 (0.51-1.72), p=0.84] and inflammation scores [OR 1.16 (0.61-2.22), p=0.64] and greater odds of achieving low osteitis scores [OR(95% CI) 2.06(1.10-3.84), p=0.02] versus normal weight patients.

Conclusions: Obese patients with RA have lower rates of DAS28 remission but similar rates of low MRI activity compared to non-obese patients, suggesting that obesity and its associated comorbidities can bias clinical disease activity measures.
INTRODUCTION

Obesity is one of the most common comorbid conditions among patients with rheumatoid arthritis (RA). Numerous studies have suggested that patients with obesity have a poorer response to treatment and lower likelihood of achieving RA disease remission.[1–6] While some have concluded that obesity is associated with more refractory RA, an alternative explanation is that obesity and its related symptoms and comorbidities directly influence and bias specific components of disease activity measures.[7]

Magnetic resonance imaging (MRI) can be used to assess both damage and inflammatory activity in RA. MRI measured synovitis and osteitis (bone edema) are sensitive to change and have been used as outcome measures in clinical trials. These measures are also predictive of progressive joint damage independent of clinical disease activity.[8–10] Recently, thresholds for low MRI activity have been defined and validated using RA magnetic resonance imaging scores (RAMRIS). These thresholds identify patients unlikely to have structural progression, even if definitions of clinical remission are not met.[10]

The objective of this study was to compare the impact of obesity on attaining different clinical and imaging definitions of low activity and remission. We hypothesized that obese patients would be less likely to attain clinical remission but equally likely to meet MRI imaging definitions of low activity versus non-obese patients.
METHODS

The study population comes from secondary analysis of the GO-BEFORE (Clinicaltrials.gov identifier NCT00361335) and GO-FORWARD (NCT00264550) randomized, multicenter, double-blind, placebo-controlled trials which evaluated the efficacy of tumor necrosis factor alpha (TNFa) antagonist golimumab for the treatment of RA. Both studies compared golimumab in combination with methotrexate to methotrexate or golimumab monotherapy. GO-BEFORE studied methotrexate naïve patients and GO-FORWARD studied patients with inadequate methotrexate response. Detailed methods and results of both studies have previously been published.[11,12] The trials were conducted according to the Declaration of Helsinki. The secondary analysis of de-identified trial data was considered exempt by the Internal Review Board at the University of Pennsylvania.

This analysis includes the subset of patients in both studies who had MRIs scored for synovitis, osteitis, and/or bone erosion at baseline and during follow up. Patients ≥18 years old who met American College of Rheumatology 1987 criteria for RA and had active disease were recruited into the MRI sub-study at participating sites. Data collection at each 4-week visit through 52 weeks included blinded assessments of Disease Activity Score in 28 joints [DAS28(CRP)] and Health Assessment Questionnaire (HAQ). MRI was performed at baseline, week 24, and week 52. Body mass index at baseline was calculated as weight in kilograms divided by height in meters squared, and
categorized as BMI <20 (underweight), BMI 20-<25 (normal weight), BMI 25-<30 (overweight), and BMI ≥30 (obese).

MRIs of the dominant wrist and 2\textsuperscript{nd}-5\textsuperscript{th} metacarpophalangeal (MCP) joints were obtained using a 1.5T MRI with contrast enhancement as previously described and scored by two independent blinded readers using the RAMRIS scoring system.[9] Low synovitis and low osteitis scores were defined as ≤3 based on recently defined thresholds.[10] Inflammation scores were calculated by adding the synovitis score to twice the osteitis score as previously described, with a low score defined as ≤9.[10]

Clinical remission was defined as a DAS28(CRP) score <2.6. Thresholds for a low swollen joint count, tender joint count, patient global score, and CRP in mg/dL were all defined as ≤1 and low HAQ as ≤0.5 as defined in the 2011 ACR/EULAR Boolean definitions of remission.[13]

Data was analyzed with STATA 13.1 software (StataCorp, LP, College Station, TX). Differences in demographics, disease activity, and MRI measures at baseline across BMI categories were evaluated with Chi-square, ANOVA, and Kruskall Wallis tests. In the primary analysis, multivariable logistic regression models evaluated the association between BMI category (normal BMI as the reference) and each of the 24-week clinical disease activity or imaging outcomes, adjusting for age, sex, race, anti-cyclic citrullinated peptide (CCP) antibody status, study, and treatment assignment. The probability of
reaching low activity thresholds was determined from these models for each BMI category at the means of all covariates and displayed graphically. Secondary analysis evaluated the same outcomes at 52 weeks.

RESULTS

Baseline characteristics of the 470 patients in the cohort are shown in Table 1. Overweight and obese patients were older and more often white. Overweight and obese patients had higher tender joint counts and worse HAQ scores at baseline, although DAS28(CRP) scores were similar across BMI categories. As has been previously published from this cohort, overweight and obese subjects had substantially lower osteitis (bone edema) scores and fewer erosions at baseline (Table 1).[14]

At 24 weeks, DAS28(CRP) remission was present in 28% of underweight, 28% of normal weight, 27% of overweight, but only 17% of obese patients. After adjustment, obese patients were less likely to achieve DAS28(CRP) remission [OR (95% CI): 0.47 (0.24-0.92), p=0.03] or a low HAQ [OR: 0.49 (0.28-0.89), p=0.02] compared to normal weight patients (Figure 1) (Supplemental Table 1). Results using SDAI, CDAI, or Boolean remission were similar although not statistically significant (Supplemental Figure 1).

Obese patients were also less likely to have a favorable patient global score ≤1 [OR: 0.47 (0.24-0.92), p=0.03] and less likely to have a CRP ≤1 mg/dL [OR: 0.44 (0.23-0.84), p=0.01] at 24 weeks. Results were similar with adjustment for baseline DAS28(CRP) (not shown).
In contrast, low synovitis scores ≤3 and low inflammation scores ≤9 on MRI occurred at similar rates across BMI groups, while low osteitis (bone edema) scores were more common in obese patients (69% of obese versus 50% of normal weight patients, p=0.02). In multivariable models, obese patients were not less likely to have low synovitis [OR: 0.94 (0.51-1.72), p=0.84] or low inflammation scores [OR: 1.02 (0.53-1.96), p=0.95] at 24 weeks versus normal weight patients (Figure 2) (Supplemental Table 2). Obese patients were more likely to achieve a low osteitis score compared to normal weight patients [OR: 2.06 (1.10-3.84), p=0.02]. The odds of a low osteitis score was similar across BMI categories after adjusting for baseline osteitis (obese versus normal weight OR: 1.01 (0.40-2.51), p=0.99).

Analyses at 52 weeks were similar except that obese patients were significantly less likely to have a low tender joint count versus normal weight patients [OR: 0.47 (0.27-0.82), p=0.01] and differences in achieving low HAQ were not significant (Supplemental Table 2).

**DISCUSSION**

Obesity was associated with a lower likelihood of achieving DAS28 remission among patients with RA enrolled in these clinical trials. In contrast, these same obese patients achieved low MRI activity at a similar rate compared to non-obese patients. These results suggest that obesity is not associated with more severe or refractory RA, but
rather that obesity may bias clinical disease activity measures and thereby reduce the likelihood of achieving remission based on clinical assessments.

Patients with obesity were less likely to have low DAS28 scores at 24 and 52 weeks. Obese patients were also less likely to achieve a low patient global score, tender joint count, CRP level, and HAQ. These results support previous studies demonstrating that RA patients with obesity have worse subjective disease activity measures at baseline and poorer response of these subjective measures to treatment.[3,4,15,16] Inflammatory markers such as CRP, although considered more objective, may also be elevated in patients with obesity independent of RA disease activity.[17]

In contrast, obese patients had similar rates of achieving a low MRI synovitis or total inflammation score and higher rates of achieving a low osteitis score at 24 and 52 weeks (similar rates when controlling for baseline osteitis). These observations are supported by previous studies showing that obesity is associated with a lower risk of radiographic and MRI joint damage progression.[14,18,19] This study provides new evidence that obesity is not associated with more severe or refractory disease by showing that obese patients achieve similar rates of low MRI disease activity despite apparent differences in clinical responses.

This study utilizes clinical trial data that includes rigorous assessment of clinical disease activity measures and blinded MRI scoring at regular intervals. A “gold standard”
assessment of disease activity does not exist and MRI may not capture all aspects of RA disease activity. MRI does, however, provide an objective measure of inflammatory joint disease, a key and defining feature of RA. While very low levels of synovitis or osteitis may be common and nonspecific,[20] our use of validated cutoff scores that identify an informative degree of inflammatory disease is an advance over previous literature. Residual confounding by unmeasured factors is also possible in this observational study, although adjustment for baseline demographics, race, CCP antibody positivity, and baseline disease activity did not substantially impact the results.

In conclusion, although obese patients with RA are less likely to achieve DAS28 remission, they have similar rates of achieving low MRI activity. This study addresses an ongoing controversy about the impact of obesity on RA disease activity and suggests that obesity is not associated with more refractory RA. These results highlight the critical role of the clinician, whose challenge is to recognize the importance and limitations of disease activity measures and to consider the impact of comorbidities on disease activity scores and symptoms.

ACKNOWLEDGMENTS

Dr. George was supported by the Rheumatology Research Foundation Scientist Development Award. Dr. Baker would like to acknowledge the support of a Veterans Affairs Clinical Science Research & Development Career Development Award (IK2 CX000955). The contents of this work do not represent the views of the Department of
the Veterans Affairs or the United States Government. PE and PGC are supported in part by the National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**DISCLOSURES**

MD George and JF Baker have nothing to disclose. PG Conaghan has done speakers bureaus or consultancies for Abbvie, BMS, Janssen, Lilly, Novartis, Pfizer, and Roche. P Emery has received consulting fees, speaking fees, and/or honoraria from Pfizer, Merck, Abbvie, UCB, Roche, BMS, Lilly, and Novartis (less than $10,000 each). DG Baker is an employee of Janssen Biotech, Inc. M Østergaard has received fees for consultancy or speaker fees and/or research support from Abbott, AbbVie, BMS, Boehringer-Ingelheim, Celgene, Centocor, Eli-Lilly, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Sanofi, Schering-Plough, Roche, UCB, Takeda and Wyeth.
Table 1: Baseline characteristics of the study population by BMI group

<table>
<thead>
<tr>
<th></th>
<th>BMI &lt;20 N = 51</th>
<th>BMI 20-&lt;25 N = 164</th>
<th>BMI 25-&lt;30 N = 152</th>
<th>BMI ≥30 N = 103</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>43 (84%)</td>
<td>136 (83%)</td>
<td>126 (83%)</td>
<td>87 (84%)</td>
<td>0.98</td>
</tr>
<tr>
<td>Age, years</td>
<td>44 ± 14</td>
<td>47 ± 12</td>
<td>51 ± 11</td>
<td>52 ± 11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>15 (29%)</td>
<td>92 (56%)</td>
<td>106 (70%)</td>
<td>87 (84%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Black</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>1 (1%)</td>
<td>0.61</td>
</tr>
<tr>
<td>Asian</td>
<td>35 (69%)</td>
<td>61 (37%)</td>
<td>25 (16%)</td>
<td>7 (7%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other</td>
<td>1 (2%)</td>
<td>11 (7%)</td>
<td>20 (13%)</td>
<td>8 (8%)</td>
<td>0.05</td>
</tr>
<tr>
<td>GO-BEFORE</td>
<td>26 (51%)</td>
<td>94 (57%)</td>
<td>89 (59%)</td>
<td>61 (59%)</td>
<td>0.78</td>
</tr>
<tr>
<td>GO-FORWARD</td>
<td>25 (49%)</td>
<td>70 (43%)</td>
<td>63 (41%)</td>
<td>42 (41%)</td>
<td>0.78</td>
</tr>
<tr>
<td>CCP positive</td>
<td>39 (76%)</td>
<td>136 (83%)</td>
<td>121 (80%)</td>
<td>75 (73%)</td>
<td>0.25</td>
</tr>
<tr>
<td>DAS28(CRP)</td>
<td>5.5 ± 1.2</td>
<td>5.3 ± 1.1</td>
<td>5.6 ± 1.1</td>
<td>5.5 ± 1.0</td>
<td>0.06</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>8.9 ± 6.0</td>
<td>8.7 ± 5.1</td>
<td>9.9 ± 5.8</td>
<td>9.7 ± 5.8</td>
<td>0.19</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>12.2 ± 7.4</td>
<td>11.5 ± 6.9</td>
<td>14.4 ± 7.5</td>
<td>13.8 ± 7.0</td>
<td>0.002</td>
</tr>
<tr>
<td>Patient global</td>
<td>6.3 ± 2.4</td>
<td>5.7 ± 2.4</td>
<td>6.0 ± 2.4</td>
<td>6.0 ± 2.2</td>
<td>0.41</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.3 ± 0.7</td>
<td>1.3 ± 0.7</td>
<td>1.6 ± 0.7</td>
<td>1.7 ± 0.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>1.2 [0.4-3.6]</td>
<td>1.0 [0.3-2.4]</td>
<td>0.9 [0.4-2.3]</td>
<td>0.9 [0.4-2.0]</td>
<td>0.59</td>
</tr>
<tr>
<td>RAMRIS scores at baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synovitis</td>
<td>7.9 [4.5-13.5]</td>
<td>8.0 [4.3-12.0]</td>
<td>9.0 [5.0-12.5]</td>
<td>7.5 [4.0-10.8]</td>
<td>0.07</td>
</tr>
<tr>
<td>Osteitis</td>
<td>8.0 [1.0-19.5]</td>
<td>8.0 [1.5-18.4]</td>
<td>4.5 [1.4-10.1]</td>
<td>3.0 [0.5-9.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Bone erosion</td>
<td>14.5 [8.7-37.0]</td>
<td>16.4 [9.0-40.0]</td>
<td>14.0 [9.5-22.5]</td>
<td>13.5 [8.3-20.0]</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Mean ± SD compared with ANOVA, median [IQR] compared with Kruskall Wallis, proportions compared with Chi-square.

BMI: body mass index in kg/m². DAS28(CRP): disease activity score using 28 joints and CRP. CRP: C-reactive protein. RAMRIS: rheumatoid arthritis magnetic resonance imaging scores
Figure 1: Rates of low disease activity measures at 24 weeks among different BMI
groups. Predicted probabilities were obtained from multivariable logistic regression
models at the means of age, sex, race, cyclic citrullinated peptide antibody status, study,
treatment assignment.
* p <0.05; BMI = body mass index; DAS28 = disease activity score in 28 joints using CRP;
SJC = swollen joint count; TJC = tender joint count; PTGL = patient global VAS score; CRP
= C-reactive protein; HAQ = health assessment questionnaire

Figure 2: Rates of low clinical disease activity or low MRI scores at 24 weeks among
different BMI groups. Predicted probabilities were obtained from multivariable logistic
regression models at the means of age, sex, race, cyclic citrullinated peptide antibody
status, study, treatment assignment.
* p <0.05; BMI = body mass index; DAS28 = disease activity score in 28 joints using C-
reactive protein
References


19 van der Helm-van Mil AHM, van der Kooij SM, Allaart CF, et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in